Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Disease comorbidity-guided drug repositioning: a case study in schizophrenia.

AMIA ... Annual Symposium proceedings. AMIA Symposium - 1 Jan 2018

Wang QuanQiu, Xu Rong

Abstract excerpt

The key to any computational drug repositioning is the availability of relevant data in machine-understandable format. While large amount of genetic, genomic and chemical data are publicly available, large-scale higher-level disease and drug phenotypic data are limited. We recently constructed a large-scale disease-comorbidity relationship knowledge base (dCombKB) and a comprehensive drug-treatment relationship...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Comorbidity
Share to Databases, Factual

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Discovery

Share to Drug Repositioning

Share to Information Storage and Retrieval

Share to Knowledge Bases

Share to Natural Language Processing

Source

Open in PubMed Open full text

Identifiers

PMID: 30815174
PMCID: PMC6371343

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Disease comorbidity-guided drug repositioning: a case study in schizophrenia.PMID 30815174Read ↗

PhenoPredict: A disease phenome-wide drug repositioning approach towards schizophrenia drug discovery.Semantic proximity Read ↗

When GWAS meets the Connectivity Map: drug repositioning for seven psychiatric disordersSemantic proximity Read ↗

Uncovering novel therapeutics for schizophrenia: a multitarget approach using the CANDO platformSemantic proximity Read ↗

Systematic drug repositioning for a wide range of diseases with integrative analyses of phenotypic and molecular data.Semantic proximity Read ↗

Pathway and network embedding methods for prioritizing psychiatric drugsSemantic proximity Read ↗

Unveiling the molecular basis of disease co-occurrence: towards personalized comorbidity profilesSemantic proximity Read ↗

Translating GWAS Findings Into Therapies For Depression And Anxiety Disorders: Drug Repositioning Using Gene-Set Analyses Reveals Enrichment Of Psychiatric Drug ClassesSemantic proximity Read ↗

Gene-set analysis based on the pharmacological profiles of drugs to identify repurposing opportunities in schizophrenia.Semantic proximity Read ↗

Target-Based Drug Repositioning Using Large-Scale Chemical-Protein Interactome Data.Semantic proximity Read ↗

Leveraging the genetics of psychiatric disorders to prioritize potential drug targets and compounds.Semantic proximity Read ↗

An Integrated Knowledge Graph and Network Medicine Pipeline for Drug Repurposing: Benchmarking Across Human Diseases and Application to Amyotrophic Lateral SclerosisSemantic proximity Read ↗

Disentangling the contribution of disease genes to drug therapeutic and side effectsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.